Special Issue

Cardiovascular Disease Risk Stratification in the Era of Machine Learning and Personalized Medicine

Message from the Guest Editor

Machine learning (ML) has been promisingly applied in cardiovascular medicine in recent years, both for disease diagnosis and in prognosis prediction. Compared with traditional statistical techniques, ML algorithms can analyze variables by performing greater numbers of mathematical operations and better define complex relationships between risk factors and outcomes of interest, strengthening the predictive process. The extraction and integration of data from various possible sources (clinical measurements and observations, biological -omics, experimental results, wearable devices) make cardiovascular disease particularly suitable for the application of ML techniques. However, at present, the lack of generalizability, reproducibility, and standardized methodologies for developing and validating ML-based prognostic models reduces the quality of the available evidence and limits their implementation in clinical practice. The Special Issue aims to collect original research articles and reviews that will provide updates and future perspectives regarding the application and implementation of ML to the risk stratification of patients suffering from cardiovascular disease.

Guest Editor

Dr. Franca Dipaola

- 1. Internal Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, 20089 Milan, Italy
- 2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy

Deadline for manuscript submissions

closed (25 October 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/117857

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

